Prelude Therapeutics: Initial Ownership Filing
Ticker: PRLD · Form: 3 · Filed: Apr 28, 2026 · CIK: 0001678660
| Field | Detail |
|---|---|
| Company | Prelude Therapeutics Inc (PRLD) |
| Form Type | 3 |
| Filed Date | Apr 28, 2026 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: insider-ownership, form-3, sec-filing
Related Tickers: PRLD
TL;DR
RA Capital & execs just bought into Prelude Therapeutics. Big moves coming?
AI Summary
On April 28, 2026, Prelude Therapeutics Inc. filed a Form 3, an initial statement of beneficial ownership. This filing indicates that RA Capital Healthcare Fund LP, RA CAPITAL MANAGEMENT, L.P., Peter Kolchinsky, and Rajeev M. Shah have acquired beneficial ownership of securities in Prelude Therapeutics Inc. The filing date for this report was April 28, 2026, with a period of report ending April 21, 2026.
Why It Matters
This Form 3 filing signifies the initial acquisition of beneficial ownership of securities by key entities and individuals in Prelude Therapeutics, potentially indicating new strategic interests or investments.
Risk Assessment
Risk Level: low — A Form 3 filing is a routine disclosure of initial beneficial ownership and does not inherently indicate a change in the company's financial health or operational risk.
Key Players & Entities
- Prelude Therapeutics Inc (company) — Issuer
- RA Capital Healthcare Fund LP (company) — Reporting Person
- RA CAPITAL MANAGEMENT, L.P. (company) — Reporting Person
- Kolchinsky Peter (person) — Reporting Person
- Shah Rajeev M. (person) — Reporting Person
FAQ
What is the purpose of a Form 3 filing?
A Form 3 filing is an initial statement of beneficial ownership of securities, required for individuals or entities who become a beneficial owner of more than 10 percent of any class of a company's equity securities, or who are officers or directors of the issuer.
Who are the reporting persons in this filing?
The reporting persons are RA Capital Healthcare Fund LP, RA CAPITAL MANAGEMENT, L.P., Peter Kolchinsky, and Rajeev M. Shah.
What is the filing date and period of report for this document?
The filing date is April 28, 2026, and the period of report is April 21, 2026.
What is the CIK for Prelude Therapeutics Inc?
The CIK for Prelude Therapeutics Inc is not fully provided in the text, but the filing is associated with accession number 0001231919-26-000420.
Where are the business and mailing addresses for the reporting entities?
The business and mailing addresses for RA Capital Healthcare Fund LP, RA CAPITAL MANAGEMENT, L.P., and Peter Kolchinsky are listed as 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116. Rajeev M. Shah's business and mailing address is 175 INNOVATION BOULEVARD, WILMINGTON DE 19805.
Filing Details
This Initial Statement of Beneficial Ownership (Form 3) was filed with the SEC on April 28, 2026 by RA Capital Healthcare Fund LP regarding Prelude Therapeutics Inc (PRLD). Form 3 filings establish the initial ownership position of company insiders when they first assume their role.